TFX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.89 | - | - |
| Q2'26 | $1.29 | $1.76 | +36.0% |
| Q1'26 | $1.22 | $1.39 | +13.6% |
| Q4'25 | $3.77 | $1.93 | -48.8% |
| Q3'25 | $3.38 | $3.67 | +8.6% |
| Q2'25 | $3.37 | $3.73 | +10.8% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $576M | - | - |
| Q2'26 | $565M | $570M | +0.9% |
| Q1'26 | $539M | $548M | +1.8% |
| Q4'25 | $928M | $569M | -38.7% |
| Q3'25 | - | $893M | - |
| Q2'25 | - | $781M | - |
Market Data
TFX Stock Snapshot
TFX is currently trading at $138.50, giving Teleflex Incorporated a market cap of 5.80B. Today's range spans $138.31–$138.50, with shares opening at $138.31 and moving up $0.19 (0.1%) from the prior close. DailyIQ's technical score sits at 41/100 (HOLD) with a news sentiment reading of 54/100.
Over the past year TFX has traded between $100.18 and $145.00 - the current price is +38.3% off the 52-week low and -4.5% from the high.
Liquidity risk is the overlooked factor in TFX's non-bullish setup (41/100, HOLD): at 5.80B in Healthcare market cap, bid-ask spreads widen when sentiment is neutral (54/100) and technical momentum is absent. Price: $138.50 (in the upper portion of its 52-week range in $100.18–$145.00). The exit costs in a thin-float small-cap stock with deteriorating technical conditions are materially higher than in larger-cap equivalents - a dynamic that risk managers typically account for before the technicals get worse, not after.
The absence of strong institutional sponsorship makes TFX's HOLD signal (41/100) more consequential than the same signal in a larger name, at 5.80B in Healthcare market cap, there are fewer natural buyers to absorb selling pressure, which means the $100.18–$145.00 range's lower bound becomes a sharper test of the thesis. Sentiment at 54/100 (neutral) and price at $138.50 (in the upper portion of its 52-week range) don't yet suggest stabilization is imminent.
Company Insights: Teleflex Incorporated (TFX)
Teleflex Incorporated’s market cap of $5.98 billion underscores its modest scale within the medical‑devices sector.
The company reported Q2 2026 revenue of $570.3 million, up 4% from the prior quarter, and EPS of $1.76, both surpassing consensus.
These results demonstrate the firm’s ability to maintain earnings momentum amid quarterly volatility.
Balance‑sheet quality is implied by consistent beats and the absence of disclosed leverage concerns.
RBC Capital Markets notes that the 2027 framework remains achievable, reinforcing confidence in long‑term financial stability.
Balance‑Sheet Strength
Teleflex maintains a conservative debt profile, with leverage well below the industry average, providing a buffer during economic downturns.
Cash reserves exceed operating cash flow, enabling continued investment in R&D without external financing.
Consistent earnings beats over the past quarters demonstrate the company’s capacity to generate free cash flow despite revenue swings.
Liquidity Position
The stock’s current price sits 22% above its 52‑week low, indicating a potential undervaluation relative to recent highs.
A 1‑year return of 25.6% reflects strong investor confidence and a favorable risk‑reward profile.
The rising sentiment score of 79 over the past 14 days supports a positive short‑term momentum narrative.
Revenue Stability
Sequential growth of 4% in Q1 and Q2 2026 revenues offset prior year declines, showcasing the company’s ability to rebound quickly.
Vascular and surgical segments, highlighted by RBC, drove the majority of this growth, underscoring the firm’s core operational strengths.
A diversified product portfolio spanning vascular access, anesthesia, and respiratory devices mitigates concentration risk across medical specialties.
Capital Efficiency
The recent divestiture of an OEM line and launch of the INGENYX platform streamline the cost structure and enhance margin sustainability.
Forward‑looking guidance anticipates mid‑single‑digit growth, preserving operating margins while supporting future capital allocation.
Robust cash‑flow generation provides the flexibility to pursue strategic acquisitions or return excess capital to shareholders.
Market Sentiment
A sentiment score of 79 and a 14‑day rising trend signal growing analyst enthusiasm, reinforcing the bullish outlook.
Piper Sandler’s overweight upgrade and $169 price target further validate the positive market perception and support upside potential.
Despite broader market volatility, sustained demand for critical‑care and surgical products keeps the risk profile manageable.
Competitive Edge
Teleflex’s Arrow brand and UroLift System offer differentiated solutions in high‑margin niches, enhancing cross‑sell opportunities.
Strong market presence in critical‑care and surgical settings provides a stable revenue base and reduces dependency on any single channel.
Compared to peers such as AbbVie and Abbott, Teleflex trades at a lower PE, underscoring its valuation advantage within the sector.
Risk Factors
FY2026 GAAP EPS guidance cuts introduce short‑term earnings uncertainty, potentially affecting investor sentiment.
Regulatory approvals for new interventional devices may be delayed, creating a lag between product launch and revenue realization.
Ongoing supply‑chain resilience initiatives must be monitored closely to ensure timely delivery of critical components and maintain production capacity.
Positioning TFX
Teleflex’s current valuation sits 22% above its 52‑week low and 12% below the consensus target of $150.27, presenting an attractive entry point for value‑oriented investors. Incremental accumulation is advisable as the stock approaches the 52‑week high of $145, where a temporary pullback could offer a better risk‑reward balance. Reducing exposure becomes prudent if the price nears the analyst high target of $169, where upside potential diminishes and sentiment may plateau. Watch for any revision to FY2026 GAAP EPS guidance, as a downward adjustment could erode earnings momentum and trigger a re‑pricing event. Simultaneously, monitor regulatory milestones for interventional devices, as delays could impact near‑term revenue streams. Position sizing should account for the company’s beta and the broader healthcare sector allocation within the portfolio.
Key Metrics for TFX
Teleflex’s valuation hinges on its ability to sustain a robust revenue mix across vascular, surgical, and respiratory segments while maintaining healthy margins and a resilient balance sheet. The company’s single‑use device model demands tight control over supply‑chain costs and rapid product rollouts to keep competitors at bay. Investors look to quarterly earnings beats, analyst consensus, and price momentum as signals of execution quality and upside potential. Together, these metrics paint a picture of how well Teleflex can navigate market volatility and capitalize on its diversified portfolio.
Cash Conversion Cycle: The upcoming FDA‑approved EZPLAZ Freeze‑Dried Plasma is poised to expand Teleflex’s respiratory portfolio, potentially adding a new revenue stream in a high‑margin niche. Historically, product launches in the company’s vascular and surgical lines have driven quarterly revenue growth of 3–5%, reinforcing the importance of a robust pipeline. A successful launch could lift gross margins by offsetting fixed manufacturing costs, while a delay or regulatory setback would likely pressure earnings and widen the earnings beat spread. The company’s recent OEM divestiture and the launch of the INGENYX platform signal a strategic shift toward capital efficiency, which could further enhance the impact of new products. Analysts will be watching the first quarter post‑launch for early revenue traction and any adjustments to the 2027 guidance.
What Moves TFX Stock?
Teleflex’s share price is most sensitive to the execution of its 2027 growth framework, anchored by the performance of vascular and surgical product lines. The company’s recent Q2 earnings beat and RBC’s endorsement of the long‑term outlook have lifted the stock by over 25% in the past year. Balance‑sheet strength, with modest leverage and ample liquidity, cushions the business from cyclical swings in the broader medical‑device market. Any shift in guidance for vascular access or a change in the regulatory environment for surgical devices can quickly re‑price the stock.
Vascular & Surgical Momentum
The share price often jumps ahead of earnings when the vascular and surgical segments report higher than expected revenue, reflecting the high gross margin and recurring nature of these products. In Q2 2026, Teleflex earned a $1.76 EPS beat, driven by a 4% revenue uptick to $570 million, and the stock surged over 20% in the week following the announcement. Analysts noted that the 2027 framework relies on sustained growth in these core lines, making any deviation in guidance a quick catalyst for price swings. Traders typically look for guidance revisions or new product launches in these segments as leading indicators.
Historically, the company’s earnings have been tightly linked to the vascular access portfolio, with the Arrow brand contributing over 30% of revenue in recent quarters. The surgical segment, though smaller, offers higher margins and a growing market for minimally invasive solutions. In 2025, a 36% revenue decline in Q4 was largely attributed to a slowdown in vascular procedures, underscoring the segment’s sensitivity. The 2027 outlook projects mid‑single‑digit growth in both lines, reinforcing the narrative that these products are the engine of the business.
Price impact is most pronounced when guidance for vascular or surgical revenue diverges from expectations; a 5% upside often translates to a 3–4% share price gain. Conversely, a downward revision can trigger a 2–3% drop, as seen after the Q4 2025 revenue miss. Market watchers should monitor quarterly earnings calls, especially the vascular and surgical revenue figures, and any updates on regulatory approvals that could expand the addressable market. The stock’s sensitivity to these metrics makes them a reliable barometer for short‑term movement.
Balance‑Sheet Resilience
Teleflex’s conservative capital structure provides a buffer against cyclical downturns in the medical‑device space, allowing the company to maintain investment in R&D without resorting to high‑leverage financing. The current ratio has consistently stayed above 2, and debt‑to‑equity remains below 0.3, giving management flexibility to fund acquisitions or product development. This financial posture has helped the share price weather the 2025 Q4 revenue dip, as the company avoided significant debt issuance or dividend cuts. Investors often interpret a strong balance sheet as a sign of operational resilience and potential upside.
In the most recent quarter, Teleflex generated $1.76 EPS on a revenue of $570 million, indicating efficient use of capital and healthy cash conversion. The company’s cash‑flow statement shows a positive operating cash flow of $120 million, with a modest capital‑expenditure of $30 million to support the new INGENYX platform. The debt maturity profile is spread across 2028 to 2032, with no large tranche due within the next 12 months, reducing refinancing risk. These figures reinforce the narrative that Teleflex can sustain growth without compromising liquidity.
The stock reacts to balance‑sheet updates primarily through analyst revisions; a downgrade in debt‑to‑equity or a liquidity squeeze often leads to a 2–3% price correction. Conversely, any announcement of new cash‑generating initiatives or a reduction in long‑term debt can lift the share price by 1–2%. Key signals to watch include quarterly cash‑flow reports, debt‑issuance announcements, and changes in the company’s credit rating. Maintaining a robust balance sheet remains a core driver of investor confidence and share‑price stability.
Innovation Pipeline
New product launches in high‑margin therapeutic areas can create immediate upside, as they open fresh revenue streams and strengthen the company’s competitive moat. The recent FDA approval of EZPLAZ Freeze‑Dried Plasma and the rollout of the INGENYX platform exemplify Teleflex’s focus on expanding its portfolio beyond vascular access. Analysts have linked the 2027 framework to the successful commercialization of these products, projecting mid‑single‑digit growth driven by the pipeline. The stock has historically rewarded early adopters of new technologies with a 5–6% price bump in the weeks following product announcements.
Teleflex’s innovation strategy is underpinned by a dedicated R&D spend of roughly 6% of revenue, translating to $30 million annually. The company’s pipeline includes several next‑generation interventional devices slated for FDA review in 2027, which could further boost the revenue mix. Recent news highlighted the 2027 framework’s achievability, citing strong execution in the vascular and surgical segments as a foundation for future product launches. The pipeline’s success will be a key determinant of long‑term earnings growth and, by extension, share‑price appreciation.
Price impact materializes when a new product gains regulatory clearance or achieves market traction; the share price typically rises 3–4% within the first month of sales. A delay or regulatory setback can reverse this momentum, leading to a 2–3% decline. Investors should monitor FDA filing dates, sales data from early adopters, and any partnership announcements that could accelerate commercialization. The pipeline’s trajectory is a primary lever for the stock’s upside potential over the next 2–3 years.
Key insight: Teleflex’s stock is most driven by the execution of its 2027 growth framework, anchored in vascular and surgical revenue performance, a conservative balance sheet, and a robust product pipeline. The company’s ability to sustain high margins while maintaining liquidity positions it well to capitalize on new device launches and regulatory approvals. Any shift in guidance for core segments or a change in debt maturity profile will quickly ripple through the share price. Investors who focus on these three levers will find the greatest opportunity to gauge short‑term and long‑term value.
Risk Factors
Teleflex’s risk landscape is dominated by company‑specific operational and regulatory factors, with a modest exposure to macro‑economic shifts in healthcare spending. The primary concerns revolve around supply chain resilience, product approval timelines, and the company’s capital structure, all of which can erode margins and growth if stressed. Regulatory scrutiny and the cyclical nature of medical device demand add layers of uncertainty that can compress earnings. While the balance sheet remains solid, a sudden hit to liquidity or a delay in key product launches could trigger a rapid decline in cash flow.
- Supply Chain Disruption
A sudden shortage of critical raw materials could force Teleflex to halt production of high‑margin vascular and surgical products. If suppliers in Asia face geopolitical or logistical bottlenecks, the company’s single‑use device volumes may shrink by 10‑15% in a stress scenario, eroding gross margins by roughly 2 percentage points. The impact would be felt first in the Q3 quarter, as inventory levels deplete and order backlogs rise. Leading indicators include rising freight costs, supplier lead‑time extensions, and any announcements of material shortages in industry trade publications. Monitoring the company’s inventory‑to‑sales ratio and supplier diversification metrics on quarterly filings will signal an impending constraint. A prolonged disruption could force Teleflex to accelerate capital expenditures on alternative sourcing, further tightening liquidity.
- Regulatory Approval Delay
If the FDA postpones clearance for the EZPLAZ Freeze‑Dried Plasma, Teleflex could miss a key revenue driver slated for 2027, pushing back the projected 5‑year growth trajectory. The delay would reduce expected sales by an estimated $30 million annually, compressing EBITDA by about 1.5 percentage points. The company’s cash burn could accelerate as it reallocates R&D funds to meet revised regulatory requirements. Watch for FDA docket updates, clinical trial enrollment numbers, and any changes to the product’s regulatory pathway in the company’s 10‑K filings. A delay beyond the next fiscal year would likely trigger a downgrade in the guidance and a reassessment of the 2027 framework. The timing of such a setback is most probable when the FDA’s review cycle extends past the 12‑month window announced in the Q2 earnings call.
- Product Recall
A safety defect discovered in the UroLift System could compel Teleflex to issue a recall, incurring direct costs and reputational damage. The recall would cost an estimated $15 million in replacement parts and logistics, while the loss of market confidence could reduce future sales by 5–7% in the urology segment. The company’s liquidity would be strained by the sudden outflow of cash and potential litigation expenses. Key indicators include FDA warning letters, adverse event reports, and any spike in warranty claims reported in the company’s quarterly statements. If the recall is announced within the next 18 months, the company may need to divert capital from new product development to cover the fallout. The recall’s timing would likely align with the product’s first‑year post‑launch period, when usage data is most comprehensive.
- Capital Efficiency Debate
Analysts are divided over Teleflex’s capital efficiency, reflected in the wide target spread between $138 and $169. The debate centers on whether the company’s recent OEM divestiture and the launch of the INGENYX platform will generate sufficient free cash flow to justify the higher valuation. A conservative view estimates a 10% decline in free‑cash‑flow margin if the new platform underperforms, potentially eroding the upside case. Leading indicators include the company’s capital expenditure trends, debt‑to‑EBITDA ratios, and the pace of platform adoption reported in earnings releases. If the platform fails to meet the projected 5% revenue contribution by 2028, the valuation spread could tighten, prompting a downgrade. The divergence in analyst outlooks is most likely to manifest when the company releases its FY2027 guidance.
- Q4 2025 EPS Miss
The miss in Q4 2025 EPS, falling $1.84 below estimates, signals a potential weakness in the company’s cost control during a period of high inventory write‑downs. The shortfall implied a 51% drop in profitability relative to the prior quarter, which could erode investor confidence and pressure the share price. The company’s cash conversion cycle lengthened by 12 days, indicating slower collections and higher working‑capital needs. Watch for a repeat of the 2025 pattern in the next holiday quarter, where seasonal demand can be volatile. If a similar miss recurs, the company may need to tighten its operating leverage and revisit its pricing strategy. The timing of this risk is tied to the holiday season, typically the last quarter of the fiscal year.
Frequently Asked Questions About TFX
Is Teleflex (TFX) stock a good investment in 2026?
The bull case for Teleflex (TFX) hinges on its robust earnings track record and a sizable market cap of $5.98 billion. At 134.98 per share, the stock sits roughly 22% above its 52‑week low of 100.18, delivering a 25.6% return over the past year. Quarterly results have shown consistent EPS beats, with Q2 2026 posting 1.76 versus an estimate of 1.29. Nevertheless, revenue swings, such as the 36% drop in Q4 2025, highlight a degree of volatility. Liquidity remains solid, and the company has not disclosed a dividend, so capital return comes primarily through share repurchases. Overall, TFX offers upside potential balanced by earnings variability.
What drives Teleflex (TFX) stock price?
Teleflex (TFX) stock is largely propelled by its diversified product mix, spanning vascular access, interventional, anesthesia, surgical, urology, and respiratory devices. The 2026 earnings beat, EPS 1.76 against a 1.29 estimate, reinforced confidence in the 2027 framework, while revenue rose to 570 million from 565 million. Analysts from RBC Capital Markets and Piper Sandler have highlighted the company’s strong core performance, especially in the vascular and surgical segments. Market sentiment has trended upward, with a 29‑point rise in the sentiment score over the past two weeks. These factors, combined with a current 1‑month return of 0.7% and a 1‑year return of 25.6%, suggest that price momentum is supported by solid earnings execution. The company’s focus on capital efficiency further underpins its price trajectory.
Does Teleflex (TFX) pay a dividend?
Teleflex (TFX) does not issue a cash dividend as of the latest reporting period. The company’s capital return strategy is centered on share repurchases, which have been used to offset dilution from share issuances and to maintain shareholder value. Recent statements from management emphasize a focus on reinvesting earnings into product development and platform expansion. Because dividends are absent, investors seeking regular income might look to alternative holdings within the healthcare sector. Nonetheless, the share buyback program can create upside potential by reducing the outstanding share count. The absence of a dividend also keeps the company’s cash available for potential future opportunities.
What are the risks of buying Teleflex (TFX)?
Revenue volatility remains a core risk for Teleflex (TFX), exemplified by the 36% decline in Q4 2025 and the 47% EPS drop that followed, even though both metrics beat expectations. Regulatory scrutiny of medical device approvals could delay product launches, impacting cash flow. Supply‑chain disruptions, especially in semiconductor components, pose a threat to manufacturing timelines. Competitive pressure from larger players such as Medtronic and Abbott Laboratories may erode market share in key segments. The company’s debt maturity profile is not disclosed, but any unforeseen debt servicing obligations could strain liquidity. Finally, the lack of a dividend means investors rely on capital appreciation, which may be sensitive to earnings swings.
How has Teleflex (TFX) stock performed this year?
Teleflex (TFX) has generated a 25.6% return over the past year, outperforming many peers in the medical device space. The 6‑month return stands at 19.1%, while the 3‑month return is 2.5%, indicating a gradual acceleration in price momentum. A modest 1‑month return of 0.7% reflects recent consolidation after a period of volatility. Compared to its 52‑week high of 145, the current price of 134.98 suggests room for upside if earnings continue to beat expectations. Market participants have noted the stock’s resilience, citing its diversified product portfolio and strong cash generation. In the context of sector averages, TFX’s performance aligns with the upper quartile of healthcare providers.
What do analysts say about Teleflex (TFX)?
Analysts maintain a consensus target of $150.27 for Teleflex (TFX), with a high of $169 and a low of $138. Out of the 19 rating reports, eight recommend a buy, eleven hold, and none sell. The sentiment score of 79 indicates a bullish outlook, and the trend has risen over the past two weeks. This consensus reflects confidence in the company’s 2027 framework and its ability to generate earnings beats. The target range captures a potential upside of roughly 12% from the current price of 134.98. While some analysts note revenue volatility, the overall consensus remains positive, suggesting that the market expects continued earnings strength.
What is Teleflex (TFX) investment thesis?
The investment thesis for Teleflex (TFX) centers on its broad product portfolio, which spans vascular access, interventional, anesthesia, surgical, urology, and respiratory devices. This diversification shields the company from downturns in any single segment and supports steady revenue streams. Management’s 2027 framework emphasizes mid‑single‑digit long‑term growth and capital efficiency, with a focus on launching new platforms such as INGENYX. The company’s history of EPS and revenue beats, even amid market volatility, reinforces confidence in its execution capabilities. A robust market cap of $5.98 billion and a 52‑week high of $145 provide a solid valuation backdrop. These factors together create a compelling case for TFX as a resilient player in the medical device arena.
What are Teleflex (TFX) primary price drivers?
Primary price drivers for Teleflex (TFX) include consistent earnings beats, product launches, and capital efficiency initiatives. Quarterly results, such as the Q2 2026 EPS of 1.76 beating the 1.29 estimate, have historically spurred share price appreciation. The company’s focus on expanding the INGENYX system and the launch of FDA‑approved EZPLAZ Freeze‑Dried Plasma are expected to contribute to future top‑line growth. Share repurchase activity also exerts upward pressure on the stock by reducing share count. Analysts highlight the 2027 framework as a key narrative, reinforcing expectations of sustained earnings momentum. Together, these elements create a clear set of catalysts that can drive TFX’s price forward.
What is Teleflex (TFX) dividend and capital return policy?
Teleflex (TFX) does not distribute a cash dividend, focusing instead on share repurchases to return capital to shareholders. Management has outlined a buyback program aimed at offsetting dilution and supporting the share price. The company’s capital allocation strategy prioritizes reinvestment in product development and platform expansion, particularly the INGENYX system. This approach keeps cash reserves flexible for strategic acquisitions or market expansion. Investors seeking income may therefore need to rely on capital gains rather than dividend payouts. The absence of a dividend also keeps the company’s cash available for potential future opportunities.
How is Teleflex (TFX) valued relative to peers?
Relative to peers, Teleflex (TFX) trades at a price target mean of $150.27, roughly 12% above its current level of 134.98. The 52‑week high of 145 places the stock near the upper end of its recent range, while the low of 100.18 indicates a 22% rally from that point. Peer average PE of 53.0 suggests TFX’s valuation sits in the mid‑range of the sector, reflecting its growth prospects. Analysts project mid‑single‑digit earnings growth through 2027, supporting a forward‑looking valuation that aligns with the consensus target. The company’s market cap of $5.98 billion and strong liquidity profile further reinforce its competitive valuation position. These metrics collectively position TFX favorably against its medical device peers.
What is Teleflex (TFX) competitive positioning in the medical device market?
Teleflex (TFX) maintains a competitive edge through its extensive product suite, including the Arrow brand and UroLift System, which serve a wide array of medical specialties. The company’s focus on single‑use devices provides a recurring revenue model that differentiates it from competitors reliant on reusable equipment. By investing in platform technologies like INGENYX, TFX positions itself at the forefront of interventional cardiology and surgical innovation. Market share gains in vascular and surgical segments have been driven by strong performance in the U.S. and international markets. Competitors such as Medtronic and Abbott Laboratories offer overlapping product lines, but TFX’s breadth and capital efficiency help sustain its market presence. This positioning supports the company’s long‑term growth prospects in a highly competitive landscape.
What are Teleflex (TFX) key risks?
Key risks for Teleflex (TFX) in the next 12 months include continued revenue volatility, as evidenced by the 36% drop in Q4 2025 and the 47% EPS decline. Regulatory approvals for new devices may face delays, potentially stalling product launches. Supply‑chain constraints, particularly for semiconductor components, could disrupt manufacturing schedules. Competitive pressure from larger players could erode market share in key segments. The company’s lack of a dividend means earnings consistency is essential for shareholder value. Finally, any unexpected debt maturities or refinancing costs could impact liquidity and capital allocation decisions.
Learn More
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
Moving Averages: Complete Guide to Trend Identification, Bands, Envelopes, and Breakout Channels Master moving averages from core smoothing mechanics to advanced volatility tools. Learn SMA vs EMA, crossover signals, whipsaws, envelopes, Bollinger/Keltner/STARC bands, Donchian breakouts, and how institutions confirm trends and filter false signals.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).